Northwest Biotherapeutics Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 105

Employees

  • Stock Symbol
  • NWBO

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.13
  • (As of Friday Closing)

Northwest Biotherapeutics General Information

Description

Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

Contact Information

Website
www.nwbio.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda, MD 20814
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda, MD 20814
  • United States
+1 (240)

Northwest Biotherapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Northwest Biotherapeutics Stock Performance

As of 20-Nov-2026, Northwest Biotherapeutics’s stock price is $0.13. Its current market cap is $229M with 1.81B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.13 $0.14 $0.12 - $0.34 $229M 1.81B 4.42M -$0.03

Northwest Biotherapeutics Financials Summary

As of 30-Sep-2026, Northwest Biotherapeutics has a trailing 12-month revenue of $2.86M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 320,213 438,318 433,391 867,856
Revenue 2,856 1,378 1,382 1,932
EBITDA (27,405) (49,667) (73,967) (55,625)
Net Income (39,664) (60,162) (83,778) (62,599)
Total Assets 76,137 81,290 26,728 27,865
Total Debt 69,835 64,827 67,440 45,560
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Northwest Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Northwest Biotherapeutics‘s full profile, request access.

Request a free trial

Northwest Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. Th
Drug Discovery
Bethesda, MD
105 As of 2025

Boston, MA
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Northwest Biotherapeutics Competitors (58)

One of Northwest Biotherapeutics’s 58 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
Astex Pharmaceuticals Corporate Backed or Acquired Cambridge, United Kingdom
Liquidia Formerly VC-backed Morrisville, NC
BeOne Medicines Formerly PE-Backed Beijing, China
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
You’re viewing 5 of 58 competitors. Get the full list »

Northwest Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Northwest Biotherapeutics Acquisitions (3)

Northwest Biotherapeutics’s most recent deal was a Merger/Acquisition with Advent Bioservices. The deal was made on 24-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Advent Bioservices 24-Oct-2025 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Flaskworks 28-Aug-2020 Merger/Acquisition Other Devices and Supplies
MithraGen 01-Jan-2008 Merger/Acquisition Biotechnology
To view Northwest Biotherapeutics’s complete acquisitions history, request access »

Northwest Biotherapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Northwest Biotherapeutics’s complete esg history, request access »

Northwest Biotherapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Advent Bioservices Cambridge, United Kingdom 2016

Northwest Biotherapeutics FAQs

  • When was Northwest Biotherapeutics founded?

    Northwest Biotherapeutics was founded in 1996.

  • Where is Northwest Biotherapeutics headquartered?

    Northwest Biotherapeutics is headquartered in Bethesda, MD.

  • What is the size of Northwest Biotherapeutics?

    Northwest Biotherapeutics has 105 total employees.

  • What industry is Northwest Biotherapeutics in?

    Northwest Biotherapeutics’s primary industry is Drug Discovery.

  • Is Northwest Biotherapeutics a private or public company?

    Northwest Biotherapeutics is a Public company.

  • What is Northwest Biotherapeutics’s stock symbol?

    The ticker symbol for Northwest Biotherapeutics is NWBO.

  • What is the current stock price of Northwest Biotherapeutics?

    As of 20-Nov-2026 the stock price of Northwest Biotherapeutics is $0.13.

  • What is the current market cap of Northwest Biotherapeutics?

    The current market capitalization of Northwest Biotherapeutics is $229M.

  • What is Northwest Biotherapeutics’s current revenue?

    The trailing twelve month revenue for Northwest Biotherapeutics is $2.86M.

  • Who are Northwest Biotherapeutics’s competitors?

    Aura Biosciences, Astex Pharmaceuticals, Liquidia, BeOne Medicines, and ADC Therapeutics are some of the 58 competitors of Northwest Biotherapeutics.

  • What is Northwest Biotherapeutics’s annual earnings per share (EPS)?

    Northwest Biotherapeutics’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process